公开(公告)号：US20240156806A1

公开(公告)日：2024-05-16

申请号：US18496134

申请日：2023-10-27

申请人： Corcept Therapeutics Incorporated

发明人： Grace Mann ,  Iulia Cristina Tudor ,  William Guyer ,  Hazel Hunt ,  Joseph Custodio

IPC分类号： A61K31/4738 ,  A61K31/4152 ,  A61K31/428 ,  A61P25/28

CPC分类号： A61K31/4738 ,  A61K31/4152 ,  A61K31/428 ,  A61P25/28

摘要： Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated as




Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.